Paclitaxel and docetaxel in prostate cancer

Hematology/Oncology Clinics of North America

Volumn 15, Issue 3, 2001, Pages 525-545

  Obasaju, C ^a   Hudes, G R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCL S ANTISENSE; CARBOPLATIN; DEXAMETHASONE; DISCODERMOLIDE; DOCETAXEL; EPOTHILONE A; EPOTHILONE B; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; HYDROCORTISONE; MACROLIDE; MICROTUBULE INHIBITOR; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROTEIN INHIBITOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CROSS RESISTANCE; DOSE RESPONSE; DRUG METABOLISM; DRUG TOLERABILITY; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PROSTATE CANCER; REVIEW; STEROID THERAPY; TUMOR REGRESSION;

EID: 0034883764     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70230-6     Document Type: Article

References (101)

1. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and independent human xenograft models
2. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate
3. The microtubule-affecting drug paclitaxel has antiangiogenic activity
4. Loss of cell cycle control allows selective microtubule-active drug-induced bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells
5. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
6. Taxol induction of p21Waf1 and p53 requires c-raf-1
7. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action
8. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
9. Pharmacologic characterization of multidrug resistant MRP-transfected human tumor cells
10. Docetaxel
11. Weekly estramustine, taxotere, and dexamethasone in patients with hormone refractory prostate cancer
12. Estramustine depolymerizes microtubules by binding to tubulin
13. Paclitaxel (Taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells
14. A phase II trial of mitoxantrone/paclitaxel in hormone-refractory prostate cancer
15. Taxol differentially modulates the dynamics of microtubule assembled from unfractionated and purified β-tubulin isotypes
16. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer
17. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition
18. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587)
19. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies
20. Mechanisms of action and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death
21. Evidence for a nonestrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo
22. Phase I and pharmacokinetic study of taxotere (RP 56976, NSC 628503) given as a short intravenous infusion
23. A Phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2
24. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization
25. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGRR-1 in human prostate cancer
26. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
27. Expression of a multidrug resistance gene in human cancers
28. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer
29. Bcl-2 is the guardian of microtubule integrity
30. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
31. Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor α
32. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial
33. Phase II study of estramustine and vi nblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
34. Phase I clinical and pharmacokinetic study of intravenous estramustine phosphate
35. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
36. Phase I study of paclitaxel and estramustine: Preliminary activity in hormone-refractory prostate cancer
37. Phase II study of weekly paclitaxel by 1-hour infusion plus reduced-dose oral estramustine in metastatic hormone-refractory prostate carcinoma
38. Novel mechanism of resistance to paclitaxel (Taxol) in human leukemia K562 cells by combined selection with PSC 833
39. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death
40. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
41. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to taxol
42. Taxol resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
43. Paclitaxel, estramustine, and carboplatin in patients with advanced prostate cancer
44. Intravenous (IV) estramustine, paclitaxel, and carboplatin in patients with advanced prostate cancer
45. Protein prenylation: Key to ras function and cancer intervention?
46. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow
47. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone-refractory prostate carcinoma
48. Phase I trial of estramustine phosphate and infusional paclitaxel administered over 3 hours every 3 weeks for the treatment of hormone-refractory prostate cancer (HRPC)
49. Interaction of estramustine with tubulin isotypes
50. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis
51. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line
52. Potentiation of apoptosis in human cancer cell lines by synergistic combination of taxol and discodermolide
53. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
54. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen-independent prostate cancer
55. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
56. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
57. Famesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
58. Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations
59. A Phase I/IIA dose-escalating trial of Bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies
60. Phase I/II trial of estramustine with taxotere or vinorelbine in patients with metastatic hormone-refractory prostate cancer
61. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumor in transforming growth factor (TGF) α and TGFα/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
62. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer
63. Microtubule dynamics in vitro are regulated by the tubulin isotype composition
64. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action
65. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
66. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
67. Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo
68. L and bak expression
69. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
70. IV-tubulin in human prostate carcinoma cells as a result of estramustine resistance
71. III isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents
72. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
73. Her2 expression in androgen-independent prostate cancer
74. Studies with RP56976 (taxotere), a semisythetic analogue of taxol
75. Preclinical antitumor activity of BMS-188797, a new paclitaxel analog
76. Taxol in advanced, hormone refractory carcinoma of the prostate: A Phase II trial of the Eastern Cooperative Oncology Group
77. ras. GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity
78. A Phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B Trial 9780
79. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms
80. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin
81. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial endpoint in hormone-refractory prostatic cancer
82. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells
83. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer
84. Addition of Herceptin (humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase II trial
85. Modulation of p-glycoprotein activity by estramustine is limited by binding to plasma proteins
86. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
87. P-glycoprotein binding and modulation of the MDR phenotype by estramustine
88. Steroid-sensitive proteins, growth hormone and somatomdein C in prostatic cancer: Effects of parenteral and oral estrogen therapy
89. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines
90. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells
91. Chemotherapy with mitoxantrone and prednisone for symptomatic hormone refractory prostate cancer patients: A Canadian randomized trial with palliative end points
92. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
93. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug
94. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine
95. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53
96. Mechanisms of taxol-induced cell death are concentration dependent
97. Weekly 1-hour infusion of paclitaxel: Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma
98. A Phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
99. Microtubule-interfering agents activate c-jun N-terminal kinase/stress activated protein kinase through both ras and apoptosis signal-regulating kinase pathways
100. Taxol induces tyrosine phosphorylation of shc and its association with grb2 in murine Raw 264.7 cells